Recombinant vesicular stomatitis virus-based vaccines against Ebola and marburg virus infections

Thomas Geisbert, Heinz Feldmann

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

The filoviruses, Marburg virus and Ebola virus, cause severe hemorrhagic fever with a high mortality rate in humans and nonhuman primates. Among the most-promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (rVSV) that expresses a single filovirus glycoprotein (GP) in place of the VSV glycoprotein (G). Importantly, a single injection of blended rVSV-based filovirus vaccines was shown to completely protect nonhuman primates against Marburg virus and 3 different species of Ebola virus. These rVSV-based vaccines have also shown utility when administered as a postexposure treatment against filovirus infections, and a rVSV-based Ebola virus vaccine was recently used to treat a potential laboratory exposure. Here, we review the history of rVSV-based vaccines and pivotal animal studies showing their utility in combating Ebola and Marburg virus infections.

Original languageEnglish (US)
JournalJournal of Infectious Diseases
Volume204
Issue numberSUPPL. 3
DOIs
StatePublished - Nov 1 2011

Fingerprint

Ebola Hemorrhagic Fever
Marburgvirus
Vesicular Stomatitis
Vaccines
Viruses
Ebolavirus
Ebola Vaccines
Primates
Glycoproteins
Fever
History
Injections
Mortality
Infection

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Recombinant vesicular stomatitis virus-based vaccines against Ebola and marburg virus infections. / Geisbert, Thomas; Feldmann, Heinz.

In: Journal of Infectious Diseases, Vol. 204, No. SUPPL. 3, 01.11.2011.

Research output: Contribution to journalArticle

@article{3a1507d4b47d4f5d8c613df26bfbdb80,
title = "Recombinant vesicular stomatitis virus-based vaccines against Ebola and marburg virus infections",
abstract = "The filoviruses, Marburg virus and Ebola virus, cause severe hemorrhagic fever with a high mortality rate in humans and nonhuman primates. Among the most-promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (rVSV) that expresses a single filovirus glycoprotein (GP) in place of the VSV glycoprotein (G). Importantly, a single injection of blended rVSV-based filovirus vaccines was shown to completely protect nonhuman primates against Marburg virus and 3 different species of Ebola virus. These rVSV-based vaccines have also shown utility when administered as a postexposure treatment against filovirus infections, and a rVSV-based Ebola virus vaccine was recently used to treat a potential laboratory exposure. Here, we review the history of rVSV-based vaccines and pivotal animal studies showing their utility in combating Ebola and Marburg virus infections.",
author = "Thomas Geisbert and Heinz Feldmann",
year = "2011",
month = "11",
day = "1",
doi = "10.1093/infdis/jir349",
language = "English (US)",
volume = "204",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Recombinant vesicular stomatitis virus-based vaccines against Ebola and marburg virus infections

AU - Geisbert, Thomas

AU - Feldmann, Heinz

PY - 2011/11/1

Y1 - 2011/11/1

N2 - The filoviruses, Marburg virus and Ebola virus, cause severe hemorrhagic fever with a high mortality rate in humans and nonhuman primates. Among the most-promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (rVSV) that expresses a single filovirus glycoprotein (GP) in place of the VSV glycoprotein (G). Importantly, a single injection of blended rVSV-based filovirus vaccines was shown to completely protect nonhuman primates against Marburg virus and 3 different species of Ebola virus. These rVSV-based vaccines have also shown utility when administered as a postexposure treatment against filovirus infections, and a rVSV-based Ebola virus vaccine was recently used to treat a potential laboratory exposure. Here, we review the history of rVSV-based vaccines and pivotal animal studies showing their utility in combating Ebola and Marburg virus infections.

AB - The filoviruses, Marburg virus and Ebola virus, cause severe hemorrhagic fever with a high mortality rate in humans and nonhuman primates. Among the most-promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (rVSV) that expresses a single filovirus glycoprotein (GP) in place of the VSV glycoprotein (G). Importantly, a single injection of blended rVSV-based filovirus vaccines was shown to completely protect nonhuman primates against Marburg virus and 3 different species of Ebola virus. These rVSV-based vaccines have also shown utility when administered as a postexposure treatment against filovirus infections, and a rVSV-based Ebola virus vaccine was recently used to treat a potential laboratory exposure. Here, we review the history of rVSV-based vaccines and pivotal animal studies showing their utility in combating Ebola and Marburg virus infections.

UR - http://www.scopus.com/inward/record.url?scp=80054741833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054741833&partnerID=8YFLogxK

U2 - 10.1093/infdis/jir349

DO - 10.1093/infdis/jir349

M3 - Article

C2 - 21987744

AN - SCOPUS:80054741833

VL - 204

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - SUPPL. 3

ER -